NR3C1 and inflammatory bowel disease: Second generation glucocorticoids (GCs), such as budesonide and beclomethasone dipropionate (BDP), which are characterized by high anti‐inflammatory activity, with low systemic bioavailability due to a significant first-pass effect and higher affinity for the glucocorticoid receptor (GR) compared to first generation GCs, represent an important alternative approach for IBD therapy (3).